Forootan Mojgan, Tabatabaeifar Morteza, Fatemi Mehdi, Darvishi Mohammad
Department of Gastroenterology, Gastrointestinal and Liver Diseases Research Center (RCGLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mater Sociomed. 2019 Dec;31(4):246-252. doi: 10.5455/msm.2019.31.246-252.
Esophageal cancer is diagnosed with more than 480,000 patients per year and this disease became the eighth most common cancer worldwide.
In this study, we tried to investigate the role of chemoradiotherapy in decreasing the severity of dysphagia and increasing the quality of life (QOL) in patients with esophageal cancer.
Patients were diagnosed with esophageal cancer, which were proven by pathological studies. Also, all of these patients had no primary surgeries for their esophageal cancer. For determining the cancer staging, the endoscopy, sonography, abdominal and pelvic computed tomography scans were assessed.
In this study, 81% of patients showed responsiveness to the chemoradiotherapy and their dysphagia significantly was getting improved after treatment in comparison to the initial date (P<0.01). Also, the pain score significantly decreased after chemoradiotherapy. However, the analysis failed to show any significant difference between before and after treatment in 19% of patients who had high degrees of dysphagia and they were the candidate for surgery and stent putting. On the other hand, we demonstrated that there is no correlation between sex, age, tumor type and location with the recovery rate of dysphagia. In addition, we showed that none of the patients showed the recurrence of dysphagia during the study (1.5 years).
Chemoradiotherapy could be a novel treatment for patients with inoperable esophageal cancer to reduce the severity of dysphagia and increasing the QOL of these individuals.
每年有超过48万名患者被诊断出患有食管癌，这种疾病已成为全球第八大常见癌症。
在本研究中，我们试图探讨放化疗在降低食管癌患者吞咽困难严重程度及提高生活质量（QOL）方面的作用。
患者经病理研究确诊为食管癌。此外，所有这些患者均未接受过食管癌的初次手术。通过评估内镜检查、超声检查、腹部和盆腔计算机断层扫描来确定癌症分期。
在本研究中，81%的患者对放化疗有反应，与初始日期相比，治疗后他们的吞咽困难明显改善（P<0.01）。此外，放化疗后疼痛评分显著降低。然而，分析未能显示出在吞咽困难程度较高且适合手术和放置支架的19%患者中，治疗前后有任何显著差异。另一方面，我们证明性别、年龄、肿瘤类型和位置与吞咽困难的恢复率之间没有相关性。此外，我们表明在研究期间（1.5年）没有患者出现吞咽困难复发。
放化疗可能是治疗无法手术的食管癌患者的一种新方法，可降低吞咽困难的严重程度并提高这些患者的生活质量。
